Furthermore, it was clearly shown that madanin 1 and 2 inhibited conversion of fibrinogen into fibrin by thrombin, thrombin-catalyzed activation of factor V and factor VIII, and thrombin-i
Trang 1Identification and characterization of novel salivary thrombin
Shiroh Iwanaga1, Masakazu Okada1, Haruhiko Isawa3, Akihiro Morita2, Masao Yuda2and Yasuo Chinzei2
1
Laboratory of Chemistry and Utilization of Animal Resources, Faculty of Agriculture, Kobe University, Japan;
2
Department of Medical Zoology, School of Medicine, Mie University, Tsu, Japan
3
Laboratory of Physiology and Biochemistry, Department of Medical Entomology, National Institute of Infectious Diseases, Tokyo, Japan
Novel antithrombin molecules were identified from the
ixodidae tick, Haemaphysalis longicornis These molecules,
named madanin 1 and 2, are 7-kDa proteins and show no
significant similarities to any previously identified proteins
Assays using human plasma showed that madanin 1 and 2
dose-dependently prolonged both activated partial
throm-boplastin time and prothrombin time, indicating that they
inhibit both the intrinsic and extrinsic pathways Direct
binding assay by surface plasmon resonance measurement
demonstrated that madanin 1 and 2 specifically interacted
with thrombin Furthermore, it was clearly shown that
madanin 1 and 2 inhibited conversion of fibrinogen into
fibrin by thrombin, thrombin-catalyzed activation of factor V and factor VIII, and thrombin-induced aggregation
of platelets without affecting thrombin amidolytic activity These results suggest that madanin 1 and 2 bind to the anion-binding exosite 1 on the thrombin molecule, but not to the active cleft, and interfere with the association of fibrinogen, factor V, factor VIII and thrombin receptor on platelets with
an anion-binding exosite 1 They appear to be exosite 1-directed competitive inhibitors
Keywords: anticoagulant; Haemaphysalis longicornis; sali-vary gland; thrombin inhibitor; tick
Thrombin has various physiological functions and plays
important roles in hemostasis For example, in the final step
of blood clot formation, thrombin converts soluble
fibri-nogen into fibrin and subsequently triggers cross-linking
between fibrin monomers by activating factor XIII [1] It
also amplifies its own generation by activating
nonenzy-matic cofactors V and VIII as well as factor XI [2,3]
Conversely, it suppresses its own generation by activating
protein C [4], which inactivates factor Va and factor VIIIa
together with protein S [5], when bound to the endothelial
membrane receptor thrombomodulin In addition,
throm-bin induces platelet aggregation via proteolytic activation of
G-protein-coupled protease-activated receptors (PARs)
[6,7] Specific interactions of thrombin with these substrates,
cofactors, and receptors involve not only the catalytic site
and the primary binding pocket, but also secondary
recognition sites, termed anion-binding exosite 1 and 2
Anion-binding exosite 1 interacts with negatively charged
domains on fibrinogen [8], PARs [6,7,9], and
thrombomo-dulin [10,11] Anion-binding exosite 2 interacts with heparin
[12], promoting inhibition of thrombin by antithrombin III
[13] and heparin cofactor II [14] Furthermore, both exosites
are involved in the recognition of factor V and factor VIII
by thrombin [15]
The salivary glands of blood-sucking animals, such as leeches, insects, and ticks, contain various anticoagulants [16] These substances inhibit the host hemostatic response so that the blood-sucking organism can feed smoothly on host blood The best known anticoagulant identified from blood-sucking organisms is hirudin, a highly specific thrombin inhibitor, isolated from the medical leech, Hirudo medicinalis [17] It interacts with two distinct sites on the thrombin molecule: its N-terminal and C-terminal domains bind to the active site and anion-binding exosite 1, respectively [18,19] This binary binding mechanism appears to contribute to its potent inhibitory activity It has also been demonstrated that the peptide alone derived from the C-terminal domain of hirudin is able to inhibit various thrombin functions [20–23] This indicates that anion-binding exosite 1 is essential in interactions between thrombin and its substrates, and that competitive binding to anion-binding exosite 1 is one strategy
of thrombin inhibition
In this paper, we describe two novel anticoagulants identified from the ixodidae tick, H longicornis These molecules exhibit no sequence similarities to any previously known proteins We show that the recombinant anticoagu-lant molecules clearly prolong both activated partial thromboplastin time (APTT) and prothrombin time (PT), and specifically bind to thrombin We further demonstrate that these molecules inhibit the conversion of fibrinogen into fibrin, activation of factor V and factor VIII, and aggregation of platelets by thrombin without inhibiting thrombin amidolytic activity toward a small synthetic substrate These results suggest that these factors are novel exosite 1 competitive inhibitors like the C-terminal peptide
of hirudin
Correspondence to S Iwanaga, Laboratory of Chemistry and
Utilization of Animal Resources, Faculty of Agriculture,
Kobe University, Kobe 657-8501, Japan.
E-mail: iwanaga@ans.kobe-u.ac.jp
Abbreviations: APTT, activated partial thromboplastin time; PT,
prothrombin time; PAR, protease activated receptor; SPR, surface
plasmon resonance; RU, resonance unit.
Enzyme: Thrombin (EC 3.4.21.5).
(Received 13 November 2002, revised 1 March 2003,
accepted 7 March 2003)
Trang 2Experimental procedures
Materials
Human thrombin, bovine thrombin, human factor X/Xa,
human factor IXa, and human factor V were purchased from
Enzyme Research Laboratories The following absorption
coefficients (e0.1%,280) and molecular masses were used to
determine protein concentrations: human thrombin, 18.3,
37 kDa; bovine thrombin, 19.5, 37 kDa; human factor X,
11.6, 58.8 kDa; human factor Xa, 11.6, 46 kDa; human
factor IXa, 14.9, 56 kDa; human factor V, 9.6, 330 kDa
Human factor VIII was obtained from American
Diagnos-tica Inc., Greenwich, CT, USA and the concentration
adjusted to 0.25 UÆlL)1 Human fibrinogen was from
Sigma-Aldrich Chromogenic substrates, S-2238 and
S-2222, were obtained from AB Kabi Restriction enzyme
was purchased from Invitrogen All other reagents were
analytical grade and obtained from either Nacalai Tesque,
Kyoto, Japan or Wako Pure Chemical Industry, Osaka,
Japan
Mass sequence analysis of cDNA clones
H longicornissalivary gland mRNA was isolated from 10
pairs of glands of ticks at three distinct feeding stages
(unfed, slow feeding, and rapid feeding) by using a
QuickPrepMicro mRNA Purification Kit (Amersham
Bioscience) Three cDNA libraries were constructed from
each isolated mRNA using SuperScript Plasmid System for
cDNA Synthesis and Plasmid Cloning Kit (Invitrogen) In
total, approximately 2000 cDNA clones were picked
randomly from three libraries, and their partial DNA
sequences were determined using T7 primer and an ABI
PRISM Big Dye Terminator Cycle Sequencing Kit (Applied
Biosystems) Sequence similarity searches of clones were
carried out using theBLASTprogram at the National Center
for Biotechnology Information (NCBI) In addition, signal
peptides of deduced amino-acid sequences were predicted
using the SIGNAL PProgram at the Center for Biological
Sequence Analysis (CBS)
Expression and purification of recombinant proteins
DNA fragments encoding predicted mature regions of
recombinant proteins were amplified by PCR using each
specific primer set Amplified PCR products were subcloned
into the NdeI–HindIII site of pET22b expression vector
(Novergen) After verification of nucleotide sequences of
constructed plasmids, recombinant proteins were expressed
according to the manufacturer’s instructions Cells
expres-sing recombinant proteins were resuspended in 20 mL
50 mMTris/HCl, pH 7.5, and frozen at)20 C Cells were
thawed in ice-cold water and sonicated Cell lysates were
centrifuged, and supernatants subjected to gel-filtration
chromatography on a Sephadex G75 column (1.8· 90 cm)
Fractions containing purified recombinant proteins were
pooled and stored at)20 C until use
The purity of the recombinant proteins was confirmed by
RP-HPLC using a Wakosil 5C4 column (4.6 mm· 20 cm;
Wako) pre-equlibrated in 0.1% trifluoroacetic acid Bound
proteins were eluted with a linear gradient of 0–100%
acetonitrile/0.1% trifluoroacetic acid The molecular masses
of purified recombinant madanin 1 and 2 were determined
on a Voyager MALDI-TOF mass spectrometer (PerSeptive Biosystems) with a 337-nm N2laser and ion reflector
Assay of effects of madanin 1 and 2 on plasma coagulation
Citrated human normal plasma (20 lL) and recombinant proteins (30 lL) were preincubated for 5 min at 37C Mixtures were activated for 2 min at 37C with 30 lL 25% actin (Dade Behring) in the APTT assay and with 30 lL rabbit brain thromboplastin (Ortho Diagnostic System) in the PT assay Clotting reactions were started by the addition
of 25 lL 50 mMCaCl2, and the clotting time was measured using a coagulometer
Binding analysis using surface plasmon resonance (SPR) SPR measurement was performed using a BIAcore 3000 instrument (BIAcore) Thrombin (bovine) was immobilized
on the surface of a sensor chipCM5 by the amine coupling procedure according to the manufacturer’s instructions Binding analyses were carried out using Hepes-buffered saline (10 mMHep es, p H 7.4, 150 mMNaCl, 5 mMCaCl2, and 0.005% Tween 20) as running buffer at 25C A 40 lL volume of various concentrations of the samples was injected on to the sensor chipat a flow rate of 20 lLÆmin)1 Association was monitored during a 2-min injection of analyte Dissociation was monitored for 2 min after return
to the running buffer Regeneration of the sensor chip surface was achieved with a pulse injection of 1M NaCl The binding data were analyzed using the evaluation software (BIAevaluation) to determine the dissociation constants (Kd)
Assay of effects of madanin 1 and 2 on fibrinogenolytic activity of thrombin
Inhibition of fibrin clot formation by the recombinant proteins was measured using fibrinogen as a substrate Substrate solution was prepared by the addition of 1 part arabic gum (15%, w/v) to 7 parts fibrinogen (100 mg per
7 mL), and preincubated at 37C for 15 min Thrombin (3.9 nM, final concentration) was mixed with various concentrations of recombinant proteins, and the mixtures added to prewarmed substrate solution The prolongation of fibrin clot formation was measured using the coagulometer
Assay of effects of madanin 1 and 2 on activation of factor V and factor VIII by thrombin
The effect of the madanins on the activation of factor V by thrombin was determined as follows Factor V (240 pM, final concentration) in buffer A (50 mMTris/HCl, pH 7.5,
150 mMNaCl, 5 mMCaCl2, and 0.1% BSA) was preincu-bated for 2 min at 37C with thrombin (20 pM, final concentration) in the presence of various concentrations of the recombinant proteins and added to buffer A containing
400 nM prothrombin, 20 pM factor Xa, and 40 lM phos-pholipid After the addition of thrombin and the recom-binant proteins, the reaction mixtures were incubated for
Trang 35 min at room temperature Prothrombin activation by
prothrombinase was stopped by the addition of EDTA
(5 mM, final concentration) The activity of generated
thrombin, which reflects the amount of activated factor V
in the sample, was measured using chromogenic substrate
S-2238
The effect of the madanins on the activation of factor
VIII by thrombin was determined as follows Factor VIII
(0.15 UÆmL)1, final concentration) in buffer A was
pre-incubated for 5 min at 37C with thrombin (2.5 pM, final
concentration) and recombinant proteins, then added to
buffer A containing 400 nMfactor X, 1 nMfactor IXa, and
40 lMphospholipid The reaction mixtures were incubated
for 2 min at room temperature After the incubation, the
activity of factor Xa, which reflects the amount of activated
factor VIII, was measured using chromogenic substrate
S-2222
Assay of effects of madanin 1 and 2 on
thrombin-induced platelet aggregation
Washed platelets were prepared as follows Blood was
mixed with acid citrate dextrose, incubated for 30 min at
room temperature, and centrifuged at 300 g for 10 min
Prostaglandin E1 (PGE1) was added to the supernatant
to a final concentration of 20 ngÆmL)1 The mixture was incubated for 15 min at room temperature and centrifuged
at 1300 g for 20 min The precipitated platelets were washed three times with a modified Tyrode’s buffer (134 mMNaCl,
3 mM KCl, 0.3 mM NaH2PO4, 2 mM MgCl2, 12 mM
NaHCO3, 5 mMglucose, 5 mMHepes, 3.5 mgÆmL)1BSA,
1 mMEGTA) containing 20 ngÆmL)1prostaglandin E1and
20 ngÆmL)1apyrase The resulting platelets were suspended with Tyrode’s buffer containing 2 mMCaCl2
Inhibition of thrombin-induced platelet aggregation was measured using washed platelets Briefly, 550 lL washed platelets (3· 105 platelets per lL) in Tyrode’s buffer containing 2 mM CaCl2, 0.2 mgÆmL)1 fibrinogen, and 1.0 mM Gly-Pro-Arg-Pro peptide was preincubated at
37C for 3 min Then 50 lL of a mixture containing thrombin (0.1 nM, final concentration) and recombinant proteins was added to prewarmed washed platelets Platelet aggregation was monitored using an aggregometer Results
cDNA cloning and expression of madanin 1 and 2 Three distinct cDNA libraries were constructed from the salivary glands of H longicornis at different feeding stages:
1-GCTTTGACCGCAATGAAGCACTTCGCAATTTTGATTCTTGCTGTTGTGGCCAGTGCCGTG
- M K H F A I L I L A V V A S A V
61-GTGATGGCATACCCGGAGAGAGATTCAGCGAAGGAGGGCAACCAAGAGCAAGAGAGAGCT
-V M A Y P E R D S A K E G N Q E Q E R A
121-CTGCATGTAAAGGTACAAAAACGTACTGATGGTGATGCTGACTACGATGAATATGAGGAA
-L H V K V Q K R T D G D A D Y D E Y E E
181-GATGGGACGACTCCTACTCCGGATCCAACTGCACCAACTGCTAAACCACGGCTTCGAGGA
-D G T T P T P D P T A P T A K P R L R G
241-AATAAGCCTTGAATCAATGATGTTCTATTTTTTATAGCGTCCCGATGGCGGTGATGTTGT
-N K P *
301-AGGCTGGAAGCAAATAAAAATACGAAGAGTGACTTCAAAAAAAAAAAAAAAAAAAAAAAA
A
1-GCTTTGACGGCAATGAAGCACTTCGTAATTTTGATTCTTGCTGTTGTGGCCAGTGCCGTG
M K H F V I L I L A V V A S A V
61-GTGATGGCATACCCGGAGAGAGATTCAGCAAAGGACGGCAACCAAGAGAAAGAGAGAGCT
V M A Y P E R D S A K D G N Q E K E R A
121-CTGCTAGTTAAAGTACAAGAACGCTATCAAGGTAATCAAGGTGACTACGATGAATATGAC
L L V K V Q E R Y Q G N Q G D Y D E Y D
181-CAAGATGAGACCACTCCTCCTCCGGATCCAACTGCACAAACTGCAAGACCACGGCTTCGA
Q D E T T P P P D P T A Q T A R P R L R
241-CAAAATCAGGATTGAATCAATGGTGTTCTAGATTTCTATAACCTACCGACGGCGGCAATT
Q N Q D *
301-TTGTGGGGTCCAAACAAATAAAACTACAAAGTGGGACCTCAAAAAAAAAAAAAAAAAAAA
B
Madanin-1 MKHFAILILAVVASAVVMAYPERDSAKEGNQEQERALHVKVQKRTDG-DADYDEYEEDGT
Madanin-2 MKHFVILILAVVASAVVMAYPERDSAKDGNQEKERALLVKVQERYQGNQGDYDEYDQDET
**** ********************** **** **** **** * * ***** * *
Madanin-1 TPTPDPTAPTAKPRLRGNKP
Madanin-2 TPPPDPTAQTARPRLRQNQD
** ***** ** **** *
C
Fig 1 Nucleotide sequences and deduced amino-acid sequences of madanin 1 and 2 The first 19 amino acids are predicted to be the signal peptide sequences for both madanin 1 (A) and madanin 2 (B) (C) Comparison of amino-acid sequences of madanin 1 and 2 Sequence alignment was performed using the ClustalW program at the Bioinformatics Center Institute for Chemical Research The same amino-acid residues are indicated by stars.
Trang 4unfed, slow feeding, and rapid feeding A total of 1889
cDNA clones were picked from three cDNA libraries, and
their partial nucleotide sequences determined Sequence
similarity searches of all cDNA clones were performed using
theBLAST program A signal peptide prediction was also
carried out using the SignalP Program, because many
physiologically active molecules identified from the salivary
gland are secreted proteins Predicted secreted proteins were
classified into several protein families based on amino-acid
sequence similarities (data not shown)
The major protein family found in the rapid feeding stage
cDNA library was named the madanin family after the
Jap anese name for H longicornis, Hutatoge-chimadani
The madanin family consists of two proteins, madanin 1
and 2 (Fig 1A,B) They exhibited no sequence similarities
to any other previously identified proteins and shared 79%
sequence identity (Fig 1C) The cDNA of madanin 1 and 2
contained 240 and 243 bpORFs encoding 79 and 80
amino-acids residues, respectively The first 19 amino acids
in both were predicted to be the signal peptide The
calculated molecular mass of the mature regions of madanin
1 and 2 were 6770.9 Da and 7122.42 Da, respectively
To investigate the biological activities of madanin 1 and 2,
the recombinant molecules were produced in Escherichia
coliBL21(DE3) cells using expression vector pET22b Their
expression was confirmed by SDS/PAGE The recombinant
proteins were purified by gel-filtration chromatography
using Sephadex G75, and purity was evaluated by
RP-HPLC (data not shown) The MALDI spectrum of
madanin 1 and 2 exhibited main [M + H]+ions of m/z
6899.39 and 7244.46, respectively (data not shown) As a
methionine residue was added to the N-terminus of the
recombinant proteins when produced using pET22b, the
experimental and calculated masses were almost identical
Madanin 1 and 2 are novel anticoagulants
ofH longicornis
It was previously reported that anticoagulants are present in
the salivary glands of H longicornis [24] According to this
report, an extract of the salivary glands prolonged both
APTT and PT, suggesting the presence of an inhibitor of
either factor Xa or thrombin However, the anticoagulant
molecule has not yet been identified To investigate the
physiological function of madanin 1 and 2, we first
examined their antihemostatic activities using normal
human plasma As shown in Fig 2, madanin 1 and 2
prolonged both APTT and PT in a dose-dependent manner,
demonstrating that they are novel anticoagulants in H
lon-gicornisand inhibit both the intrinsic and extrinsic
coagu-lation pathways
Thrombin is a target molecule of madanin 1 and 2
The results obtained from the APTT and PT assays suggest
that madanins act as inhibitors of factor Xa and/or
thrombin Thus, we investigated, by SPR using BIAcore,
their ability to bind to factor Xa and thrombin All assays
were performed twice with immobilized 821.8 resonance
units (RU) factor Xa or 1037.0 RU thrombin on sensor
chips, as described in Experimental Procedures This assay
clearly showed that madanin 1 and 2 specifically interacted
with thrombin, but not with factor Xa Both bound thrombin in a dose-dependent manner, as shown in Fig 3 From these results, it is clear that thrombin is a target molecule of madanin 1 and 2 However, the sensorgrams showed abnormal patterns, indicating poor interaction, in which the dissociation of the complex was very fast and the reaction between ligand and analyte equilibrated very rapidly
As the association and dissociation phases in the inter-actions of madanin 1 and 2 with thrombin were very short,
it was difficult to analyze the kinetic constants for the inter-action Therefore, we evaluated the equilibrium constants
Fig 2 Effect of madanin 1 and 2 on prolongation of APTT and PT The effects of madanin 1 and 2 on intrinsic and extrinsic pathways were investigated by APTT (A) and PT (B) assays, respectively Various concentrations of madanin 1 and 2 were incubated with citrated human plasma, and the mixture was activated with diluted APTT and
PT reagents After activation, CaCl 2 was added to the mixture, and clotting times were measured (s) Madanin 1; (d) madanin 2.
Trang 5usingBIAEVALUATIONsoftware according to the following
equation:
Req¼ KaC=ð1 þ KaCÞ where Reqis the value of resonance units in an equilibrated
state, Kais the association constant, and C is the
concen-tration of the analyte used in the assay Kdwas derived from
the relationship, Kd¼ 1/Ka Under the conditions of this
experiment, Kdvalues for binding of madanin 1 and 2 to the
immobilized thrombin were 4.18 and 2.96 lM, respectively
The two madanins had similar potencies for interaction with
thrombin
Madanin 1 and 2 inhibit the conversion of fibrinogen
into fibrin by thrombin
Next, we examined whether madanin 1 and 2 inhibit the
amidolytic activity of thrombin Assays were performed
using a synthetic substrate for thrombin (S-2238) Thrombin activity remained fully intact despite a 1000-fold molar excess of madanin 1 and 2 added to thrombin, indicating that they do not inhibit amidolytic activity of thrombin with
a small chromogenic substrate (data not shown)
Although madanin 1 and 2 were found by SPR meas-urements to bind to thrombin, they did not inhibit hydrolysis of small synthetic substrates by thrombin Therefore, we examined whether they inhibit cleavage of the physiological substrate, fibrinogen As shown in Fig 4, they prolonged fibrin clot formation by thrombin in a dose-dependent manner, showing that they prevented thrombin from cleaving fibrinogen and are able to inhibit the function
of thrombin without affecting its amidolytic activity The results of these two experiments suggest that thrombin inhibition by madanin 1 and 2 is caused by competitive binding to the fibrinogen-binding site (anion-binding exo-site 1) on the thrombin molecule, and not from binding to the active site
Fig 3 SPR analysis of the interaction between madanin 1 and 2 and thrombin Interactions between thrombin and madanin 1 (A) and madanin 2 (B) were investigated by SPR measurement Thrombin was immobilized on
a sensor chipat levels of 1037.0 RU Sensor-grams were obtained by injection of madanin
1 and 2 at different concentrations ranging from 0.25 l M to 5 l M at a flow rate of
20 lLÆmin)1and are indicated as solid lines The sensor chipsurface was regenerated with
1 M NaCl before each injection The inter-actions between factor Xa and madanin 1 and 2 were also investigated Factor Xa was coupled
to a sensor chipat levels of 821.8 RU The interactions were measured by injection of
5 l M madanin 1 and 2 The sensorgrams are shown as dotted lines in each case.
Trang 6Madanin 1 and 2 inhibit activation of factors V
and VIII and aggregation of platelets by thrombin
It has been reported that the anion-binding exosite 1 is
involved in molecular recognition of thrombin for factor V,
factor VIII, and PAR on platelets Therefore, we
investi-gated the effects of madanin 1 and 2 on thrombin-catalyzed
activation of factors V and VIII and thrombin-induced
aggregation of platelets As shown in Figs 5 and 6,
activation of prothrombin and factor X by prothrombinase
and tenase were inhibited, respectively, by the presence of
madanin 1 and 2 It was further confirmed that they do not
inhibit the activity of prothrombinase itself The activities of
thrombin and factor Xa in each assay reflect the amount of
factors Va and VIIIa, respectively, present Thus, it is
indicated that madanin 1 and 2 inhibit activation of factors
V and VIII by thrombin and then prevent these cofactors
from forming prothrombinase and tenase complexes On
the other hand, as shown in Fig 7, madanin 1 and 2
suppressed thrombin-induced aggregation of platelets in a
dose-dependent manner Platelet aggregation begins with
proteolytic cleavage of PAR by thrombin Therefore, these
results also support the conclusion that madanin 1 and 2 are
direct competitive inhibitors of the anion-binding exosite 1
on thrombin
Discussion
In this study, we have identified novel anticoagulants,
named madanin 1 and 2, from the salivary gland of
H longicornis This is the first description of antihemostatic
factors in H longicornis Madanin 1 and 2 prolonged both
APTT and PT, indicating that they are anticoagulants for
the common pathway of coagulation SPR analysis showed that they specifically interacted with thrombin, not with factor Xa An inhibition assay with fibrinogen as substrate showed that they inhibited the fibrinogenolytic activity of thrombin Therefore, we conclude that they inhibit blood coagulation by inhibiting the function of thrombin Madanin 1 and 2 also inhibited the activation of thrombin-catalyzed cofactors V and VIII as well as the conversion of fibrinogen into fibrin Furthermore, they inhibited thrombin-induced platelet aggregation via proteo-lytic activation of PAR However, they did not inhibit the amidolytic activity of thrombin in an assay using a synthetic
Fig 4 Effect of madanin 1 and 2 on formation of fibrin clot by thrombin.
Substrate solution containing fibrinogen and arabic gum was prepared
as described in Experimental Procedures and prewarmed at 37 C.
Thrombin and various concentrations of madanin 1 and 2 were mixed
and added to the substrate solution The time to fibrin clot formation
was measured using a coagulometer (s) Madanin 1; (d) madanin 2.
Fig 5 Effect of madanin 1 and 2 on the activation of factor V by thrombin Factor V was preincubated with thrombin in the presence of madanin 1 or 2 and added to buffer A containing prothrombin (400 n M ), factor Xa (20 p M ), phospholipid (40 l M ), and CaCl 2 (5 m M ) Thrombin activity was measured using a chromogenic sub-strate (S-2238).
Trang 7substrate It has been reported that fibrinogen and PAR
bind to the anion-binding exosite 1 on thrombin and that
anion-binding exosite 1 and 2 are involved in the
inter-actions between thrombin and its cofactors Structural data
on thrombin show that anion-binding exosite 1 and 2 are
located opposite each other on the thrombin molecule [25–
27] Taking the inhibitory profiles and molecular sizes of
madanin 1 and 2 into consideration, it is most likely that
they are competitive inhibitors directed to the anion-binding
exosite 1 of thrombin
Madanin 1 and 2 show no similarities in their amino-acid sequences to thrombin inhibitors from any blood-sucking organisms However, the clusters of acidic residues found in the central regions of madanin are similar to those found in hirudin [17], tsetse thrombin inhibitor [28,29], anophelin [30,31], and thrombostatin [32] These acidic regions show electrostatic interactions with positively charged anion-binding exosite 1 Furthermore, our recent studies indicate that N-terminally truncated madanin 1 maintains the ability
to bind to thrombin (unpublished data) Thus, madanin 1 and 2 may bind to anion-binding exosite 1 through the acidic residue clusters
The Kdvalues of madanin 1 and 2 determined by SPR analysis (4.18 and 2.96 lM, respectively) are significantly higher than those of other anion-binding exosite 1 inhibitors [17,28,31] In the SPR analysis, thrombin was immobilized
Fig 7 Effect of madanin 1 and 2 on platelet aggregation by thrombin Washed platelets were prepared as described in Experimental Proce-dures Thrombin and the madanins were mixed and added to the washed platelets (3 · 10 5 platelets per lL) in the presence of 2 m M
CaCl 2 , 0.2 mgÆmL)1fibrinogen, and 1.0 m M Gly-Pro-Arg-Pro peptide Platelet aggregation was monitored with an aggregometer Complete aggregation was obtained in the absence of madanin 1 and 2 Fig 6 Effect of madanin 1 and 2 on activation of factor VIII by
thrombin Factor VIII was preincubated with thrombin in the presence
of madanin 1 or 2 and added to buffer A containing factor X (400 n M ),
factor IXa (1 n M ), phospholipid (40 l M ), and CaCl 2 (5 m M ) Factor
Xa activity was measured using a chromogenic substrate (S-2222).
Trang 8by amine coupling In this immobilizing reaction, the
e-amino groupof the lysine residue on the anion-binding
exosite 1 of thrombin may be coupled to the carboxy group
on the sensor chip This may result in the weak interactions
observed In fact, the Kd(app) values calculated from the
results in Figs 5 and 6 by the methods of Henderson [33] are
85–170-fold lower than those obtained from SPR analysis
The Kd(app)values of madanin 1 and 2 are 25 and 34.5 nM,
respectively Therefore, it is possible that the Kdvalues of
interactions between madanins and thrombin are lower
than those determined by SPR analysis
Physiological coagulation is initiated by formation of a
factor VIIa–tissue factor complex at the injury site This
complex activates factor X, which is followed by generation
of small amounts of thrombin [34] The generated thrombin
further activates factor V and factor VIII, which leads to the
generation of a large amount of thrombin This
amplifica-tion stepis thought to be crucial for physiological
coagu-lation, as deficiencies of factor V and factor VIII cause
serious bleeding Therefore, it is possible that madanins
inhibit blood coagulation at this initial stepby inhibiting the
activation of factor V and factor VIII by thrombin and
contribute considerably to tick blood feeding
In conclusion, novel thrombin inhibitors (madanin 1 and 2)
from H longicornis have been identified They inhibit
various physiological functions of thrombin without
inter-fering with its catalytic activity and may play an important
role in tick blood feeding Recent studies report that
anion-binding exosite 1 inhibitors such as the C-terminal peptide of
hirudin are attractive therapeutic drugs for arterial
throm-bosis [35] Thus, further studies on the inhibitory mechanisms
of madanin 1 and 2 may provide useful information for the
development of therapeutic agents for thrombosis
Acknowledgements
This work was supported by a grant from the Japan Society for
Promoting Science: Future Developmental Research (to Y C.) and by
a grant from Mitsubishi Pharma Research Foundation (to S I.).
References
1 Davie, E.W., Fujikawa, K & Kisiel, W (1991) The coagulation
cascade: initiation, maintenance, and regulation Biochemistry 30,
10363–10370.
2 Kane, W.H & Davie, E.W (1988) Blood coagulation factors V
and VIII: structural and functional similarities and their
relationshipto hemorrhagic and thrombotic disorders Blood 71,
539–555.
3 Gailani, D & Broze, G.J Jr (1991) Factor XI activation in a
revised model of blood coagulation Science 253, 909–912.
4 Walker, F.J., Sexton, P.W & Esmon, C.T (1979) The inhibition
of blood coagulation by activated Protein C through the selective
inactivation of activated Factor V Biochim Biophys Acta 571,
333–342.
5 Esmon, C.T (1987) The regulation of natural anticoagulant
pathways Science 235, 1348–1352.
6 Vu, T.K., Hung, D.T., Wheaton, V.I & Coughlin, S.R (1991)
Molecular cloning of a functional thrombin receptor reveals
a novel proteolytic mechanism of receptor activation Cell 64,
1057–1068.
7 Coughlin, S.R (1999) How the protease thrombin talks to cells.
Proc Natl Acad Sci USA 96, 11023–11027.
8 Fenton, J.W II, Olson, T.A., Zanbinski, M.P & Wilner, G.D (1988) Anion-binding exosite of human alpha-thrombin and fibrin (ogen) recognition Biochemistry 27, 7106–7112.
9 Coughlin, S.R (2000) Thrombin signaling and protease-activated receptors Nature (London) 407, 258–264.
10 Wu, Q.Y., Sheehan, J.P., Tsiang, M., Lentz, S.R., Birktoft, J.J & Sadler, J.E (1991) Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin Proc Natl Acad Sci USA 88, 6775–6779.
11 Tsiang, M., Jain, A.K., Dunn, K.E., Rojas, M.E., Leung, L.K & Gibbs, C.S (1995) Functional mapping of the surface residues of human thrombin J Biol Chem 270, 16854–16863.
12 Fenton, J.W II, Witting, J.I., Pouliott, C & Fareed, J (1989) Thrombin anion-binding exosite interactions with heparin and various polyanions Ann NY Acad Sci 556, 158–165.
13 Rosenberg, R.D & Damus, P.S (1973) The purification and mechanism of action of human antithrombin-heparin cofactor.
J Biol Chem 248, 6490–6505.
14 Tollefsen, D.M., Pestka, C.A & Monafo, W.J (1982) Heparin cofactor II Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma J Biol Chem 257, 2162– 2169.
15 Esmon, C.T & Lollar, P (1996) Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII J Biol Chem 271, 13882–13887.
16 Arocha-Pinango, C.L., Marchi, R., Carvajal, Z & Guerrero, B (1999) Invertebrate compounds acting on the hemostatic mechanism Blood Coag Fibrinol 10, 43–68.
17 Markwardt, F & Walsmann, P (1967) Purification and analysis
of the thrombin inhibitor hirudin Hoppe Seylers Z Physiol Chem 348, 1381–1386.
18 Bode, W & Huber, R (1991) Refined structure of the hirudin– thrombin complex J Mol Biol 221, 583–601.
19 Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C & Fenton, J.W II (1990) The structure of a complex of recombinant hirudin and human alpha-thrombin Science 249, 277–280.
20 Naski, M.C., Fenton, J.W II, Maranagore, J.M., Olson, S.T & Shafer, J.A (1990) The COOH-terminal domain of hirudin An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen J Biol Chem 265, 13484–13489.
21 Tsiang, M., Lentz, S.R., Dittman, W.A., Wen, D., Scarpati, E & Sadler, J.E (1990) Equilibrium binding of thrombin to recom-binant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues Biochemistry 29, 10602–10612.
22 Hortin, G.L & Trimpe, B.L (1991) Allosteric changes in thrombin’s activity produced by peptides corresponding to seg-ments of natural inhibitors and substrates J Biol Chem 266, 6866–6871.
23 Vu, T.K.H., Wheaton, V., Hung, D.T., Charo, I & Coughlin, S.R (1991) Domains specifying thrombin–receptor interaction Nature (London) 353, 674–677.
24 Anastopoulos, P., Thurn, M.J & Broady, K.W (1991) Anti-coagulant in the tick Ixodes holocyclus Aust Vet J 68, 366–367.
25 Stubb, M.T & Bode, W (1993) A player of many parts: the spotlight falls on thrombin’s structure Thromb Res 69, 1–58.
26 Bode, W., Turk, D & Karshikov, A (1992) The refined 1.9-A˚ X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships Protein Sci 1, 426–471.
27 Di Cera, E., Dang, Q.D & Ayala, Y (1997) Molecular mechan-isms of thrombin function Cell Mol Life Sci 53, 701–730.
28 Cappello, M., Bergum, P.W., Vlasuk, G.P., Furmidge, B.A., Pritchard, D.I & Aksoy, S (1996) Isolation and characterization
of the tsetse thrombin inhibitor: a potent antithrombotic peptide
Trang 9from the saliva of Glossina morsitans morsitans Am J Trop Med.
Hyg 54, 475–480.
29 Cappello, M., Li, S., Ghen, X., Li, C.B., Harrison, L.,
Nara-shimhan, S., Beard, C.B & Aksoy, S (1998) Tsetse thrombin
inhibitor: blood meal-induced expression of an anticoagulant in
salivary glands and gut tissue of Glossina morsitans morsitans.
Proc Natl Acad Sci USA 95, 14290–14295.
30 Valenzuela, J.G., Francischetti, I.M.B & Ribeiro, J.M (1999)
Purification, cloning, and synthesis of a novel salivary
anti-thrombin from the mosquito Anopheles albimanus Biochemistry
38, 11209–11215.
31 Francischetti, I.M.B., Valenzuela, J.G & Ribeiro, J.M (1999)
Anophelin: kinetics and mechanism of thrombin inhibition
Bio-chemistry 38, 16678–16685.
32 Zhang, D., Cupp, M.S & Cupp, E.W (2002) Thrombostasin: purification, molecular cloning and expression of a novel anti-thrombin protein from horn fly saliva Insect Biochem Mol Biol.
32, 321–330.
33 Henderson, P.J.F (1972) A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors Biochem J 127, 321– 333.
34 Haffman, M & Monroe, D.M (2001) A cell-based model of hemostasis Thromb Haemost 85, 958–965.
35 Bates, S.M & Weitz, J.I (1998) Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin Am J Cardiol 82, 12–18.